Media headlines about OvaScience (NASDAQ:OVAS) have been trending somewhat positive on Monday, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OvaScience earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.2365636586561 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern’s rankings:
- OvaScience (OVAS) Receives Buy Rating from HC Wainwright (americanbankingnews.com)
- Hair-Raising Facts to Know – OvaScience Inc (NASDAQ: OVAS) (stockspen.com)
- Notable Movers to Watch: OvaScience, Inc., (NASDAQ: OVAS), L Brands, Inc., (NYSE: LB); (tradingnewsnow.com)
- Hot Stock That Must Be in Your Portfolio – OvaScience Inc (NASDAQ: OVAS) (stocksmarketcap.com)
- Pivoting Stocks: Enterprise Products Partners LP, (NYSE: EPD), OvaScience, Inc., (NASDAQ: OVAS) (globalexportlines.com)
Several analysts have commented on OVAS shares. Zacks Investment Research raised shares of OvaScience from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research report on Wednesday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of OvaScience in a report on Friday, March 16th.
OvaScience (NASDAQ:OVAS) last announced its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.07. OvaScience had a negative net margin of 17,338.78% and a negative return on equity of 60.06%. The company had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.10 million. sell-side analysts forecast that OvaScience will post -1.21 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “OvaScience (NASDAQ:OVAS) Getting Somewhat Favorable Press Coverage, Accern Reports” was published by BBNS and is the property of of BBNS. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://baseballnewssource.com/2018/04/02/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-ovascience-ovas-share-price/2002749.html.
OvaScience Company Profile
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.